• 1
    Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009; 46: 64-75.
  • 2
    Larson S, Stock W. Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol. 2008; 15: 400-407.
  • 3
    Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354: 166-178.
  • 4
    Rowe JM. Optimal management of adults with ALL. Br J Haematol. 2009; 144: 468-483.
  • 5
    Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006; 12: 1-30.
  • 6
    Yanada M, Matsuo K, Suzuki T, et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a meta-analysis. Cancer. 2006; 106: 2657-2663.
  • 7
    Orsi C, Bartolozzi B, Messori A, et al. Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant. 2007; 40: 643-649.
  • 8
    Cornelissen JJ, van der Holt B, Verhoef GE, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood. 2009; 113: 1375-1382.
  • 9
    Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111: 1827-1833.
  • 10
    Fielding AK Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009; 113: 4489-4496.
  • 11
    Wheatley K, Gray R. Commentary: Mendelian randomization—an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol. 2004; 33: 15-17.
  • 12
    Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. Available at: Accessed March 1, 2009.
  • 13
    Bernasconi C, Lazzarino M, Morra E. Early intensification followed by allo-BMT or auto-BMT or a second intensification in adult ALL: a randomized multicenter study. Leukemia. 1992; 6( suppl 2): 204-208.
  • 14
    Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1994; 12: 2580-2587.
  • 15
    Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood. 1995; 86: 1619-1628.
  • 16
    Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000; 14: 1353-1366.
  • 17
    Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with 4 other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 2002; 16: 1259-1266.
  • 18
    Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004; 22: 4075-4086.
  • 19
    Labar B, Suciu S, Zittoun R, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients ≥50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica. 2004; 89: 809-817.
  • 20
    Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004; 10: 3028-3037.
  • 21
    Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 2005; 90: 1346-1356.
  • 22
    Vey N, Thomas X, Picard C, et al. Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006; 20: 2155-2161.
  • 23
    Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009; 27: 911-918.
  • 24
    Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukaemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006; 108: 465-472.
  • 25
    Dhedin N, Dombret H, Thomas X, et al. Autologous stem cell transplantation in adults with acute lymphoblastic leukaemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukaemia. 2006; 20: 336-344.
  • 26
    Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia—results of the prospective multicenter LALA-94 trial. Blood. 2002; 100: 2357-2366.
  • 27
    Fiere D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukaemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukaemia. J Clin Oncol. 1993; 11: 1990-2001.
  • 28
    De Witte T, Awwad B, Boezeman J, et al. Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant. 1994; 14: 767-774.
  • 29
    Gupta V, Yi QL, Brandwein J, et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukaemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant. 2004; 33: 397-404.
  • 30
    Mrsic M, Nemet D, Labar B, et al. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukaemia. Transplant Proc. 1993; 25: 1268-1270.
  • 31
    Ringden O, Labopin M, Gluckman E, et al. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) study. Bone Marrow Transplant. 1997; 19: 963-968.
  • 32
    Suzuki R, Iida H, Taji H, et al. Bone marrow transplantation versus maintenance chemotherapy for adult acute leukaemia in first remission. Rinsho Ketsueki. 1996; 37: 1362-1137.
  • 33
    Weisdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukaemia Blood. 1997; 90: 2962-2968.